The next phase for 2025 is recalibration, Novo Nordisk sees a $120 billion wipeout and Nissan is in full "panic mode." Manus Cranny reports. Tune into "Bloomberg Brief" at 5 a.m. ET on weekdays https://trib.al/MBdFU8V
Friday, May 23
By webmaster
The next phase for 2025 is recalibration, Novo Nordisk sees a $120 billion wipeout and Nissan is in full "panic mode." Manus Cranny reports. Tune into "Bloomberg Brief" at 5 a.m. ET on weekdays https://trib.al/MBdFU8V
